Gastroenterology
Volume 137, Issue 2 , Pages 412-415 , August 2009

Do Diabetes Drugs Modify the Risk of Pancreatic Cancer?

  • Yu–Xiao Yang

      Affiliations

    • Corresponding Author InformationReprint requests Address requests for reprints to: Yu-Xiao Yang, MD, MSCE, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, 722 Blockley Hall, 423 Guardian Drive, Philadelphia, Pennsylvania 19104-6021

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA: a Cancer Journal for Clinicians. 2008;58:71–96
  2. Pannala R, Leirness JB, Bamlet WR, et al. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology. 2008;134:981–987
  3. Wang F, Gupta S, Holly EA. Diabetes mellitus and pancreatic cancer in a population-based case-control study in the San Francisco Bay Area, California. Cancer Epidemiology, Biomarkers & Prevention. 2006;15:1458–1463
  4. Bonelli L, Aste H, Bovo P, et al. Exocrine pancreatic cancer, cigarette smoking, and diabetes mellitus: a case-control study in northern Italy. [see comment] Pancreas. 2003;27:143–149
  5. Huxley R, Ansary-Moghaddam A, de Gonzalez ABerrington, et al. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer. 2005;92:2076–2083
  6. Genuth S. Insulin use in NIDDM. Diabetes Care. 1990;13:1240–1264
  7. Li D, Yeung S–CJ, Hassan MM, et al. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology. 2009;137:482–488
  8. Silverman DT, Schiffman M, Everhart J, et al. Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer. 1999;80:1830–1837
  9. Bailey CJ, Turner RC. Metformin. [see comment] N Engl J Med. 1996;334:574–579
  10. Pour PM, Kazakoff K. Stimulation of islet cell proliferation enhances pancreatic ductal carcinogenesis in the hamster model. Am J Pathol. 1996;149:1017–1025
  11. Schneider MB, Matsuzaki H, Haorah J, et al. Prevention of pancreatic cancer induction in hamsters by metformin. [see comment] Gastroenterology. 2001;120:1263–1270
  12. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. [see comment] J Clin Invest. 2001;108:1167–1174
  13. Jones RG, Plas DR, Kubek S, et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. [see comment] Molecular Cell. 2005;18:283–293
  14. Liang J, Shao SH, Xu ZX, et al. The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol. 2007;9:218–224
  15. Zakikhani M, Dowling R, Fantus IG, et al. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006;66:10269–10273
  16. Evans JMM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330:1304–1305
  17. Bowker SL, Majumdar SR, Veugelers P, et al. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. [see comment] Diabetes Care. 2006;29:254–258
  18. Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst. 2002;94:972–980
  19. Fisher WE, Boros LG, Schirmer WJ. Insulin promotes pancreatic cancer: evidence for endocrine influence on exocrine pancreatic tumors. J Surg Res. 1996;63:310–313
  20. Pour PM, Kazakoff K, Carlson K. Inhibition of streptozotocin-induced islet cell tumors and N-nitrosobis(2-oxopropyl)amine-induced pancreatic exocrine tumors in Syrian hamsters by exogenous insulin. Cancer Res. 1990;50:1634–1639
  21. Stolzenberg-Solomon RZ, Graubard BI, Chari S, et al. Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA. 2005;294:2872–2878
  22. Yang YX, Hennessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology. 2004;127:1044–1050
  23. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. [see comment] Diabetes Care. 2009;32:193–203

 Conflicts of interest The author discloses no conflicts.

PII: S0016-5085(09)00991-3

doi: 10.1053/j.gastro.2009.06.022

Gastroenterology
Volume 137, Issue 2 , Pages 412-415 , August 2009

Article Tools

* Image Usage & Resolution